Telephone numbers for medical emergencies
Acute emergencies and accidentsTel 144 (ambulance)
Poison controlTel 145 (tox center)
Operator for emergency admittanceTel +41 44 255 11 11
Emergency stroke admittanceTel +41 44 255 50 05
Data protection and social networks: We strive to safeguard your privacy. Please click at the top to share in your social networks. Data will only be sent to third parties once this function has been activated.
Data protection when sending information: We strive to safeguard your privacy. Please click at the top to send this page as an email. Data can only be sent to third parties once this function has been activated.
ContactAntonia Fettelschoss-Gabriel, PhDTel +41 44 556 3265
Group MembersVictoria Fettelschoss, MSc, Research AssociateFlorian Olomski, MSc, Research AssociateKatharina Birkmann, DVMSigridur Jonsdottir, PhDTanya Rhiner, DVM candidate
ContactsProf. Thomas Kündig, MDTel +41 44 255 3471 (secr.)Prof. Pål Johansen, PhDTel +41 44 255 8616
Main fields of researchOur research group is focused on immunotherapy of allergies, infections, and cancer. In allergy, we aim to improve efficacy and safety for immunotherapy by using novel methods or technologies. For instance, we found that administration of allergens into lymph nodes allowed shortening immunotherapy from three years of 50-60 injection to merely three injections during two months, and more recently, we are investigating the potential of allergen-specific monoclonal antibodies for use in allergen immunotherapy. We have also been strongly involved in the development of new adjuvants or particulate vaccines for immunotherapy. For instance, virus-like particles and liposomes are investigated for their potential in inducing immune responses in allergy and inflammatory skin disorders, as well as in conditions of immune suppression or deficiency, while liposomes rendered T-cell independent antibody production. Finally, we are developing a new method of cancer vaccination by combining vaccines and photodynamic therapy (PDT), a method that enables the induction of cytotoxic and tumour-specific T-cell responses. Many of our research projects are performed in collaboration with biotech companies and aim to facilitate the translation of new technologies and new treatment options into clinics and ultimately to make these available to patients.Publications (PubMed)
Group MembersTeam GloriastrasseYing Men-Wäckerle, PhDFabio Hasler, PhD studentMarta Paolucci, PhD studentZuzanna Kotkowska, PhD studentAgathe Duda, Research associate
Team SchlierenFranziska Thoms, PhDGery Jennings, PhDStefanie Haas, MSc, Research associate
ContactPD Steve Pascolo, PhD
Group MemberMarina Tusup, PhD